Cancer Treatment Reviews
Volume 31 , Pages S11-S15 , 2005

Gemcitabine-taxane experience in the treatment of metastatic breast cancer

References 

  1. Rahman ZU, Frye DK, Smith TL, et al. Results and long-term follow up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. A reference. Cancer. 1999;85(1):104–111
  2. Tubiana-Hulin M. How to maximize the efficacy of taxanes in breast cancer. Cancer Treat Rev. 2005;31(Suppl 4):3–9
  3. Gralow J. Optimising the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2005;89(Suppl 1):S9–S15
  4. Alexopoulos A, Tryfonopoulos D, Karamouzis MV, et al. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Ann Oncol. 2004;15(1):95–99
  5. Pelegri A, Calvo L, Mayordomo JI, et al. Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial. Sem Oncol. 2004;31(Suppl 5):20–24
  6. Mavroudis D, Malamos N, Alexopoulos A, et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicentre phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol. 1999;10(2):211–215
  7. Fountzilas G, Nicolaides C, Bafaloukos D, et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group phase II study. Cancer Invest. 2000;18:503–509
  8. Laufman LR, Spiridonidis CH, Pritchard J, et al. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial. Ann Oncol. 2001;12(9):1259–1264
  9. Delfino C, Caccia G, Gonzáles LR, et al. Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer. Oncology. 2004;66:18–23
  10. Colomer R, Llombart-Cussac A, Lluch A, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol. 2004;15(2):201–206
  11. (Abstract 685) Sanchez-Rovira P, Mohedano N, Moreno MA, et al. Preliminary results from an early phase II trial of combination gemcitabine and paclitaxel in metastatic breast cancer. Eur J Cancer. 1997;33(Suppl 8):S154
  12. Murad AM, Guimaraes RC, Aragao BC, et al. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. Am J Clin Oncol. 2001;24(3):264–268
  13. Abstract Vici P, Foggi P, Capomolla E, et al. Biweekly paclitaxel/gemcitabine (P/G) as salvage treatment in breast cancer patients: preliminary results. In: 2002 ASCO Meeting. 1954;
  14. Sánchez-Rovira P, Jaén A, González E, et al. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer. Clin Breast Cancer. 2000;1(3):226–232
  15. Conte PF, Gennari A, Donati S, et al. Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat. 2001;68(2):171–179
  16. July 15 Suppl Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol 2004; ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;22(14S):15
  17. Zielinski C, Beslija S, Mrsic-Krmpotic Z, et al. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group international, multicenter, prospective, randomized phase III trial. J Clin Oncol. 2005;23(7):1401–1408
  18. Levy C, Fumoleau P. Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?. Cancer Treat Rev. 2005;31(Suppl 4):17–22

PII: S0305-7372(05)80003-9

Cancer Treatment Reviews
Volume 31 , Pages S11-S15 , 2005

Article Tools